Pol Ind. la Mina Avenida de los Reyes, 1
78 articles with PharmaMar S.A.
A multicenter, international, single-arm, Phase II trial of lurbinectedin in progressive Malignant Pleural Mesothelioma (MPM) has been presented at ESMO.
Phase II study results of lurbinectedin in progressive mesothelioma will be presented in an oral session at ESMO 2019
During the European Society of Medical Oncology (ESMO) Congress, to be held from September 27th to October 1st in Barcelona, the recent results of the lurbinectedin trial for the treatment of progressive malignant pleural mesothelioma, carried out by SAKK in collaboration with PharmaMar, will be presented.
PharmaMar (MSE:PHM) presented new data on lurbinectedin during the World Conference on Lung Cancer (WCLC), which is taking place from 7th to 10th September in Barcelona.
PharmaMar Announces That Its Phase I Study on Japanese Patients With Lurbinectedin in Monotherapy Has Achieved Its Objective
This study aimed to determine the appropriate dose for Japanese patients treated with lurbinectedin, in monotherapy, for advanced solid tumors.
PharmaMar announced that the FDA agreed with PharmaMar’s proposal to file for accelerated approval its New Drug Application (NDA) for lurbinectedin monotherapy for the treatment of second-line SCLC.
Positive results of lurbinectedin Phase II trial (PharmaMar) for the treatment of relapsed small cell lung cancer are presented at ASCO
The results of PharmaMar's (MSE: PHM) Phase II study with lurbinectedin as a single agent for the treatment of relapsed small cell lung cancer were presented to the American Society of Clinical Oncology (ASCO) conference, which is currently being held in Chicago.
PharmaMar (MSE:PHM) has announced the start of its new program to develop new anti-tumor molecules.
PharmaMar is present with its ATLANTIS study at the IASLC Congress on small cell lung cancer in New York
PharmaMar (MSE:PHM) attended the third bi-annual meeting on small cell lung cancer, organized by the International Association for the Study of Lung Cancer (IASLC).
PharmaMar announces positive results in its lurbinectedin monotherapy trial for small cell lung cancer
PharmaMar (PHM:MSE) today announced that its Phase II trial of lurbinectedin as a single agent for the treatment of relapsed small cell lung cancer (SCLC) has achieved its primary endpoint, by both investigator review and IRC (Independent Review Committee).
PharmaMar’s Zepsyre® ATLANTIS trial in small-cell lung cancer will be an oral presentation at the IASLC's Targeted Therapies annual meeting
This specialized meeting is designed to provide information about ongoing clinical trials of the newest and most promising therapies for lung cancer.
The U.S. Food and Drug Administration (FDA) Has Granted Orphan Drug Designation to PharmaMar's Lurbinectedin
PharmaMar (MCE: PHM) announces that lurbinectedin has been granted orphan drug status by the FDA for the treatment of small cell lung cancer.
ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160 hospital centers in 20 countries
PharmaMar Signs a Commercialization and Distribution License Agreement for Aplidin® With Pint Pharma International
PharmaMar has announced today the signing of a commercialization and distribution license agreement with Pint Pharma International, S.A.
PharmaMar Presents in Oral Session at ASCO: The ADMYRE Study's Adjusted Overall Survival With Plitidepsin
PharmaMar has presented how crossover has had an influence on the overall survival of the ADMYRE trial.
PharmaMar Presents New Results with Lurbinectedin as a Single Agent in Patients with Recurrent Small-cell Lung Cancer at ASCO 2018
PharmaMar announced new data on the recurrent small-cell lung cancer patients cohort of the phase II basket study with lurbinectedin as a single agent, will be presented at the American Society of Clinical Oncology (ASCO) annual meeting.
Positive Recommendation of IDMC to Zepsyre® to Continue the Phase III Trial Within Small-cell Lung Cancer (ATLANTIS)
PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has notified the Company of its recommendation that the Phase III (ATLANTIS) trial currently under way with Zepsyre(R) (lurbinectedin, PM1183) in combination with doxorubicin in small-cell lung cancer patients should continue without any changes.
PharmaMar (MCE: PHM) has presented during the AACR meeting (American Association for Cancer Research) in Chicago new data about how plitidepsin works on the tumor cells.
PharmaMar Has Published the Results of its Antibody Conjugate Active in Breast, Ovarian and Gastric Cancers that Express HER2
PharmaMar has announced the positive results of MI130004, a novel antibody conjugate combining trastuzumab with PM050489, a molecule of marine origin.
PharmaMar Licenses Fully Synthetic Marine-Derived Payloads to Seattle Genetics for Use in Drug Conjugates
According to the terms of the agreement, PharmaMar receives an upfront payment of 5,000,000 US dollars on signing, followed by development milestones if a product enters clinical development conducted by Seattle Genetics.
PharmaMar has announced the initiation of the re-examination process by the EMA for Aplidin for the indication of relapsed and refractory multiple myeloma.